International Stem Cell Corp. (ISCO) to Present Final Safety and Efficacy Results from Parkinson’s Disease Program at AAN Annual Meeting
Today before the opening bell, International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced that it will be giving a platform presentation on its preclinical studies in Parkinson's at the 2015 American Academy of Neurology Annual Meeting in Washington, DC. Ruslan Semechkin, Ph.D., ISCO's chief scientific officer, will discuss the data at the "Parkinson's Disease" scientific session (s48.007), on Thursday, April 23rd at 4:45 pm in a talk entitled "Neural Stem Cell Based Therapy for Parkinson's Disease." "These animal studies strongly suggest that the transplantation of human parthenogenetic neural stem cells…